MARSEILLE, France & HOUSTON--(BUSINESS WIRE)--Vect-Horus and RadioMedix announced today the signing of a Letter of Intent (LOI) to establish an agreement for the co-development of a Vect-Horus ...

Appointment further strengthens Vect-Horus’ leadership as company continues growth and development Marseille, France, March 10, 2026 - Vect-Horus, a privately held biotechnology company that designs ...

Brings extensive experience in investor relations and financial research and analysis Will drive financial strategy to support internal pipeline and partnerships Marseille, France, March 25, 2025 - ...

MARSEILLE, France, Oct. 30, 2014 (GLOBE NEWSWIRE) -- VECT-HORUS, a biotechnology company that designs and develops peptide vectors facilitating the delivery of drugs or imaging agents, notably in the ...

MARSEILLE, France, and SEOUL, South Korea, Feb. 3, 2026 -- Vect-Horus, a France-based biotechnology company, and OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, ...

MARSEILLE, France--(BUSINESS WIRE)--Vect-Horus, a privately held biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging ...

Accomplished research scientist and business professional Brings important skills for both clinical and business development of Vect-Horus Marseille, France, November 14, 2024 - Vect-Horus, a ...

Vect-Horus and RadioMedix are pleased to announce the FDA clearance of exploratory Investigational New Drug (eIND) application to evaluate 68 Ga-RMX-VH for the detection and mapping of Low Density ...

Below is Validea's guru fundamental report for VECTIVBIO HOLDING AG (VECT). Of the 22 guru strategies we follow, VECT rates highest using our Quantitative Momentum Investor model based on the ...

Claudia Fromond, PhD, Vect-Horus Director of Research and Development (R&D). Marseille, France, March 10, 2026 - Vect-Horus, a privately held biotechnology company that designs and develops molecular ...